innovating for growth
TRANSCRIPT
![Page 1: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/1.jpg)
Innovating for GrowthDr Emma Sceats,
Chief Executive, CN Bio Innovations
London, September 7th 2017
![Page 2: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/2.jpg)
2
CASH
CUSTOMERS
COMMUNITY
![Page 3: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/3.jpg)
3
OUR Vision
To be the world leader in precision biology
replacing animal testing with accurate,
human relevant technologies
![Page 4: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/4.jpg)
4
$26m DARPA contract with the Massachusetts Institute of Technology
a Human-on-a-Chip?
![Page 5: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/5.jpg)
5
Benefits
Intellectual Property
IP Pipeline
CN Bio secured exclusive rights to commercialise all IP arising from the MIT-led DARPA consortium’s research to develop a human body-on-a-chip.
Team
Recruiting new skills
DARPA grant enabled CN Bio to hire new team members bringing specialist biology and engineering skills into our business.
Expert Collaborators
MIT Professor Linda Griffith
Professor of Biological & Mechanical engineering. Lead PI on $26M DARPA contract. US National Academy of Engineers. Recipient of MacArthur “Genius” Fellowship.
![Page 6: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/6.jpg)
6
“Ensuring that Britain remains attractive for inward investment will surely help more companies like ours access the funding needed for growth”
E. Sceats
![Page 7: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/7.jpg)
7
![Page 8: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/8.jpg)
8
Customers (early adopters)
Federal Grants & Contracts
Exports
Knowledge / IP
$$$
- Talent- Customers- Collaborators- Grants
![Page 9: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/9.jpg)
9
“As small companies endeavour to become large and internationally successful businesses
understanding the challenges and trade-offs these businesses face
will be crucial for developing policies that will nurture home-grown talent”
E. Sceats
![Page 10: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/10.jpg)
10
Ecosystem
TWO global Big Pharma companies (AZ, GSK) headquartered in UK
Thriving biotech sector from large, international players (e.g. Shire) to university spin-outs
World-class medical devices sector employing >50,000 staff
UK life sciences sector employs >233,000 people, generating £64bn revenue each year
#1 destination for foreign direct investment in Europe
![Page 11: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/11.jpg)
11
“It will be exciting to see how implementation of Sir John Bell’s recommendations can be a catalyst for growth, both for our company and our country”
E. Sceats
![Page 12: Innovating for Growth](https://reader033.vdocuments.us/reader033/viewer/2022051710/5a65b29e7f8b9a0a5f8b4973/html5/thumbnails/12.jpg)
12
Thank You